AustraliaRecent research suggests that weight-loss drugs such as Ozempic and Wegovy, which are GLP-1 agonists, may also have potential in treating addiction by reducing cravings for substances like alcohol, cocaine, amphetamines, opiates, and nicotine. These drugs mimic the GLP-1 hormone, helping regulate appetite and blood sugar levels. While their primary use is for managing type 2 diabetes and obesity, studies indicate they may affect the brain's reward system differently than previously understood. Researchers are exploring how these drugs influence brain regions beyond traditional dopamine-associated areas, such as the lateral septum, which plays a role in emotional regulation and neural connectivity.
Bias read (Center): The article discusses scientific findings related to health treatments and does not present any political positions, biases, or controversial policy discussions. It focuses on medical research and neurological mechanisms without taking a stance on political issues.
